title: Small molecule compounds targeting miRNAs for cancer therapy.
abstract: One of the most fascinating discoveries in molecular oncology has been that cancer represents a disease in which genetic alterations in protein-coding, but also in non-coding genes complement each other. MicroRNAs (miRNAs) are a type of non-coding RNA (ncRNA) transcripts that can regulate gene expression primarily by disrupting messenger RNA (mRNA) translation and/or stability, or alternatively by modulating the transcription of target mRNAs. For the last decade, miRNAs have shown to be pivotal characters of every single one of the cancer hallmarks. Profiling studies have proven the significance of identifying over-expressed miRNAs (oncomiRs) causative of the activation of oncogenic pathways that lead to malignancy. Due to their crucial role in cancer, it has become a challenge to develop efficient miRNA-inhibiting strategies such as antagomiRs, locked nucleic acids or antisense oligonucleotides. However, to this date, the accessible delivery agents and their pharmacokinetic/pharmacodynamic properties are not ideal. Thus there is an urgent, unmet need to develop miRNA-based inhibitory therapeutics. Herein we present a novel therapeutic strategy that is only at the tip of the iceberg: the use of small molecule inhibitors to target specific miRNAs (SMIRs). Furthermore we describe several high-throughput techniques to screen for SMIRs both in vitro and in silico. Finally we take you through the journey that has led to discovering the handful of SMIRs that have been validated to this date.
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Puerto Rico School of Medicine, San Juan 00936, Puerto Rico.
authors.forename: Paloma Del C
authors.initials: Pdel C
authors.lastname: Monroig
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Lu
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Shuxing
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: gcalin@mdanderson.org.
authors.forename: George A
authors.initials: GA
authors.lastname: Calin
mesh_terms: D000818:Animals; D003198:Computer Simulation; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D057166:High-Throughput Screening Assays; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009841:Oligonucleotides / Q000008:administration & dosage*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage
chemical_list: D035683:MicroRNAs; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; C477371:locked nucleic acid
keywords: Cancer; MicroRNAs; Non-coding RNAs; Small molecules; Targeted therapies